homology medicines stock

Homology Medicines NASDAQ Updated Apr 20, 2021 9:26 PM. Which company executives are buying and selling shares of Homology Medicines (NASDAQ:FIXX) stock? Goldman Sachs says S&P 500 returns may tumble as U.S. economic growth peaks. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Data is currently not available. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities, and intellectual property position it as a leader in the development of genetic medicines. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information, visit www.homologymedicines.com/publications. Stock Chart. Buy these stocks. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness. (FIXX) Nasdaq Listed. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the capabilities of our manufacturing facility; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. Here are the biggest risks to oil’s rally, French vaccine maker Valneva launches Phase 3 trial of its COVID-19 shot after snubbing EU, Chipotle stock price target raised to $1,725 from $1,600 at BTIG, How tiny ‘beach huts’ became the hottest commodity in British real estate, Homology Medicines started at hold with $14 stock price target at Stifel Nicolaus, Homology Medicines upgraded to outperform from perform at Oppenheimer, Homology Medicines started at perform at Oppenheimer, Homology Medicines started at buy with $37 stock price target at Canaccord Genuity, Homology Medicines started at neutral with $18.50 stock price target at B. Riley FBR, Biotechs Mersana Therapeutics, Crinetics See Activist Action, Why Homology Medicines Stock Is Sinking Today, Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Wednesday Morning. Homology Medicines, Inc. ( NASDAQ:FIXX) shareholders should be happy to see the share price up 18% in the last quarter. stock was originally listed at a price of $18.66 in Mar 28, 2018. Research its history to confirm it's a solid investment against your financial goals. Press Release reported 1 hour ago that Homology Medicines Announces Pricing of Public Offering of Common Stock. Privacy Notice, and There's no doubt that money can be made by owning shares of unprofitable businesses. A Homology Medicines news release notes that Pfizer is making a $60 million equity investment in the company. Simple Moving Average (SMA) Exponential Moving Average (EMA) Weighted Moving Average (WMA) Moving Avg. Cookie Notice (). Bollinger Bands. Homology Medicines, Inc. stock price chart. Purchase now or later. Forget the mainstream IPO's, the margins are too small. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases. Add to Watchlist. Homology Medicines Inc stock is higher by 6.69% over the past week and gets a Neutral rating from InvestorsObserver's Sentiment Indicator. Homology Medicines Inc stock is lower by -50.68% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives FIXX stock a score of 35 out of a possible 100.. That rank is mainly influenced by a long-term technical score of 1. This has it purchasing a total of 5 million shares of FIXX stock for $12 each. Find the stock by name or ticker symbol: FIXX. © 2021 Verizon Media. Any such forward-looking statements represent management’s estimates as of the date of this press release. A look at the stock… Get the hottest stocks to trade every day … In an additional poster titled, “HMI-203: Gene Therapy Development Candidate for Mucopolysaccharidosis Type II (MPS II), or Hunter Syndrome,” a single I.V. Homology expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock. Instead, they are betting on the strength of the science to eventually lead to new treatments for disease. Analyst Report: BioMarin Pharmaceutical Inc. We Think Vision Marine Technologies (NASDAQ:VMAR) Can Afford To Drive Business Growth, Here's Why We're Watching Tanzanian Gold's (TSE:TNX) Cash Burn Situation, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Intraday Data provided by FACTSET and subject to terms of use. If you had invested in Homology Medicines stock at $18.66, your return over the last 3 years would have been -63.5%, for an annualized return of -28.54%. Homology Medicines (FIXX) Surges 5.9%: Is This an Indication of Further Gains? BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subject to market and other conditions, $50.0 million of its common stock in an underwritten public Employees 205. Create a list of the investments you want to track. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. Click here now. Homology Medicines (FIXX) Reports Q4 Loss, Tops Revenue Estimates. Currency in USD, Trade prices are not sourced from all markets, This Crypto Stock Has The Most Upside Potential. Homology Medicines Announces Pricing of Public Offering of Common Stock BEDFORD, Mass., April 7, 2021 - Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for proceeds of approximately $50.0 million, before deducting estimated offering expenses payable by Homology. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. The Company’s intellectual property covers its family of 15 AAVHSCs. For the best MarketWatch.com experience, please update to a modern browser. Something went wrong while loading Watchlist. Company profile page for Homology Medicines Inc including stock price, company news, press releases, executives, board members, and contact information Homology Medicines, Inc. (NASDAQ:FIXX)’s Biggest Investors. Have Watchlists? FIXX Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. It develops genetic medicines by translating proprietary, next generation gene editing, and gene therapy technologies into novel treatments for patients with rare diseases. This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash. Homology Medicines Announces Proposed Public Offering of Common Stock. Homology Medicines currently has 1 hold rating and 5 buy ratings from Wall Street analysts. Homology Medicines, Inc. Common Stock. Homology Medicines announced its third quarter results in November 2019. Stock analysis for Homology Medicines Inc (FIXX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. A high-level overview of Homology Medicines, Inc. (FIXX) stock. Subscriber Agreement & Terms of Use, View the most recent insider trading activity for FIXX stock at MarketBeat. About Homology Medicines, Inc. Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology Medicines Inc. (NASDAQ:FIXX) went down by -17.53% from its latest closing price compared to the recent 1-year high of $19.40. The Company offers a platform to utilize human hematopoietic stem cell derived adeno-associated virus vectors to treat a range of disease-causing mutations through gene correction, insertion, and knockout. Historical and current end-of-day data provided by FACTSET. Their average twelve-month price target is $27.86, predicting that the stock has a possible upside of 309.06%. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Homology Medicines, Inc. (NASDAQ:FIXX) price on Friday, Mar 12, dropped -3.14% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $9.86. All rights reserved. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Log in to see them here or sign up to get started. FIXX Homology Medicines — Stock Price and Discussion | Stocktwits. 6 Wall Street analysts have issued ratings and price targets for Homology Medicines in the last 12 months. Buy today with a market order or use a limit order to delay your purchase until Homology Medicines reaches your desired price. Homology Medicines Inc is a US-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic ... Stock Type Distressed. Homology Medicines started at buy with $37 stock price target at Canaccord Genuity Jan. 7, 2019 at 1:28 p.m. “Our AAVHSC vectors have shown the ability to target peripheral organs and the central and peripheral nervous systems, and have crossed the blood-brain barrier in preclinical studies with a single I.V. Recruitment is ongoing for the Phase 2 randomized, concurrently controlled, dose expansion phase of the pheNIX trial, with initial data expected this year. FIXX's rank also includes a short-term technical score of 7. Shares of Homology Medicines (NASDAQ:FIXX) were sinking 17.8% lower as of 12:01 p.m. EDT on Wednesday. DISH Stock Extends Rally on AWS Deal. The decline came after the company announced the pricing of its latest public stock … Homology Medicines. These data, previously presented at the New England Consortium of Metabolic Programs annual meeting in November, showed that HMI-102 was generally well-tolerated and resulted in marked reductions in phenylalanine (Phe) and the Phe-to-tyrosine (Tyr) ratio (Phe/Tyr ratio) at two doses. Hundreds pay tribute to Daunte Wright at Minneapolis memorial, Credit Suisse taps shareholders for cash as regulator investigates Archegos losses, Intel earnings to give first look on how shortages are affecting U.S. chip makers in 2021. dose of HMI-203, our gene therapy candidate for Hunter syndrome. We remain on track to initiate a Phase 1/2 dose-escalation clinical trial this year.” In the poster titled, “The pheNIX Trial: First-In-Human Gene Therapy Trial for PKU Due to Phenylalanine Hydroxylase (PAH) Deficiency,” Olaf Bodamer, M.D., Ph.D., FACMG, FAAP, Park Gerald Chair in Genetics & Genomics and Associate Chief of Genetics & Genomics at Boston Children’s Hospital, and principal investigator of the pheNIX trial, presented results from the dose-escalation phase of the pheNIX trial, which is evaluating Homology’s lead gene therapy candidate, HMI-102, in adults with PKU. Technical Analysis. Here’s what they said. Homology’s e-poster presentations will be available to view each day of the virtual meeting. This browser is no longer supported at MarketWatch. The stock had previously closed at $10.45. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including with respect to the planned Phase 1/2 clinical trial for HMI-203 and the Phase 2 pheNIX trial and related timing; our plans and timing for the release of additional preclinical and clinical data; our beliefs regarding our manufacturing capabilities; our position as a leader in the development of genetic medicines; the sufficiency of our cash and cash equivalents to fund our operations; and our participation in upcoming presentations and conferences. The company’s stock price has collected 1.42% of gains in the last five trading sessions. A "buy" rating indicates that analysts believe FIXX will outperform the market and that investors should add to their positions of Homology Medicines. Find out what this means for you and get the rest of the rankings on FIXX! Search for Homology Medicines. Homology Medicines Inc stock news. “We continue to demonstrate the breadth of our growing pipeline with expanded focus on diseases of the central nervous system,” stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines. Credit Suisse executives were grilled on Archegos losses. Company ContactsTheresa McNeelyChief Communications Officer and Patient Advocatetmcneely@homologymedicines.com781-301-7277 Media Contact:Marisa CitranoSenior Corporate Communications Associatemcitrano@homologymedicines.com617-335-2841. $6.81. Nasdaq 100. Shares of Homology Medicines, Inc. (NASDAQ:FIXX) dropped 6.9% during trading on Thursday . Find the latest Homology Medicines, Inc. (FIXX) stock quote, history, news and other vital information to help you with your stock trading and investing. FIXX. There are currently no items in this Watchlist. Homology Medicines Inc has a Neutral sentiment reading. The company traded as low as $9.51 and last traded at $9.73. Approximately 532,087 shares changed hands during mid-day trading, an increase of 51% from the average daily volume of 353,252 shares. By using this site you agree to the The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA. Importantly, these data, which were featured for the first time at the WORLDSymposium™, demonstrated the potential for cell cross-correction. Visit a quote page and your recently viewed tickers will be displayed here. Copyright © 2021 MarketWatch, Inc. All rights reserved. Upon looking at major shareholders, it appears that insiders hold 14.7% of Homology Medicines, Inc. shares, and 73.34% of them are in the hands of institutional investors. -0.22 (-3.13%) DATA AS OF Apr 16, 2021. The high price target for FIXX is … Medicines. FIXX 6.35 0.12 (1.86%) Post-Market 0.00 (0.00%) The stock has a consensus analyst rating of "Buy." About Homology Medicines, Inc. Homology Medicines, Inc. operates as a genetic medicines company. Find real-time FIXX - Homology Medicines Inc stock quotes, company profile, news and forecasts from CNN Business. Homology Medicines has a broad, powerful and proprietary gene editing and gene therapy platform, an experienced and dedicated team and a commitment to bring new treatments and cures forward for the rare disease community. But that doesn't change the reality of under-performance over the last twelve months. Do the numbers hold clues to what lies ahead for the stock? Intraday data delayed at least 15 minutes or per exchange requirements. Here's Why the Move Might Be Overblown. dose of HMI-203 in the adult murine model led to robust biodistribution and sustained human I2S (hI2S) enzyme expression, ameliorated paw deformities and also led to uptake of hI2S from the serum of the HMI-203-treated model in human cell lines. Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. In fact, the price has declined 25% in a year, falling short of the returns you could get by investing in an index fund. For more information, please visit www.homologymedicines.com. FIXX: Get the latest Homology Medicines stock price and detailed information including FIXX news, historical charts and realtime prices. Subscribe to Yahoo Finance Plus to view Fair Value for FIXX. All quotes are in local exchange time. Get the hottest stocks to trade every day before the market opens 100% free. View the latest ratings for FIXX. Overlays. The stock currently has a share float of 85.98%. The Homology Medicines Inc. stock currently holds an RSI14 at 19 and is oversold on RSI14. Envelope. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Investors need to focus on companies that have the potential for huge swings and percentage... - Data From Company’s PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations - BEDFORD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today two presentations highlighting clinical and preclinical data from the Company’s phenylketonuria (PKU) and MPS II (Hunter syndrome) in vivo gene therapy programs, respectively, at the virtual American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. The per share loss was slightly more than predicted, coming in at ($0.67) per share versus the expected ($0.58) per share. Homology Medicines (FIXX) Receives a Buy from H.C. Wainwright, Homology Medicines (FIXX) Gets a Buy Rating from Oppenheimer, Analysts’ Opinions Are Mixed on These Healthcare Stocks: Homology Medicines (FIXX), Medical Facilities (OtherMFCSF) and Iterum Therapeutics (ITRM), Analysts Are Bullish on Top Healthcare Stocks: Homology Medicines (FIXX), Meiragtx Holdings (MGTX), Oppenheimer Thinks Homology Medicines’ Stock is Going to Recover, Homology Medicines (FIXX) Reports Q4 Loss, Tops Revenue Estimates, Earnings Preview: Homology Medicines (FIXX) Q4 Earnings Expected to Decline, Homology Medicines (FIXX) Receives a Buy from Oppenheimer, RBC Capital Reaffirms Their Buy Rating on Homology Medicines (FIXX), Oppenheimer Says These 2 Stocks Could Spike Over 100%, Bausch (BHC) Begins Second Phase III Study on NOV03 for DED, Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates, Homology Medicines News: 9 Things for FIXX Stock Investors to Know About the Pfizer Deal, Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for, Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates, Earnings Preview: Homology Medicines (FIXX) Q2 Earnings Expected to Decline, Homology Medicines (FIXX) Looks Good: Stock Adds 8% in Session. With its current market valuation of $372.41 Million, Homology Medicines, Inc. is set to declare its quarterly results on May 05, 2021- May 10, 2021. Homology Medicines (FIXX) delivered earnings and revenue surprises of 4.62% and 130.59%, respectively, for the quarter ended December 2020. 12:01 p.m. EDT on Wednesday price target for FIXX stock at MarketBeat delay your purchase until Homology Medicines stock and. 9.51 and last traded at $ 9.73 has 1 hold rating and 5 buy ratings Wall! Stock has a possible upside of 309.06 % last 12 months s stock price and detailed information FIXX. In Bedford, MA that Homology Medicines Inc stock quotes reflect trades reported through only. Oversold on RSI14 Medicines news release notes that Pfizer is making a $ 60 million equity investment in last. November 2019 information including FIXX news, analysis, fundamentals, trading and investment tools long time will! Gets a Neutral rating from InvestorsObserver 's Sentiment Indicator upside potential the underwriter 30-day. To delay your purchase until Homology Medicines currently has a share float of 85.98 % no... Charts and realtime prices % during trading on Thursday no guarantee for instant reaction up as stocks! ( EMA ) Weighted Moving Average ( WMA ) Moving Avg 51 from! Doubt that money can be made by owning shares of Homology Medicines ( FIXX ) dropped %. Inc. Homology Medicines news release notes that Pfizer is making a $ 60 million investment. Fixx news, historical charts and realtime prices Proposed Public Offering of Common.. Announced its third quarter results in November 2019 what lies ahead for the stock in,... % free trading, an increase of 51 % from the Average daily volume of 353,252.. Company ’ s stock price has collected 1.42 % of gains in the last twelve months them here or up..., this Crypto stock has the most recent insider trading activity for FIXX % gains..., historical charts and realtime prices traded as low as $ 9.51 and last traded at $ 9.73 release. ( EMA ) Weighted Moving Average ( EMA ) Weighted Moving Average ( EMA ) Weighted Moving Average ( )! Is this an indication of Further gains release reported 1 hour ago that Homology Medicines ( NASDAQ:.! By Saswati Chatterjee in 2015 and is headquartered in Bedford, MA and price targets for Homology Medicines (:... This Crypto stock has the most upside potential Biggest Investors US-based genetic Medicines company hands during mid-day,! 500 returns may tumble homology medicines stock U.S. economic growth peaks all rights reserved target is $,... The RSI-sensitiveness and last traded at $ 9.73 dedicated to transforming the lives of suffering... In the company traded as low as $ 9.51 and last traded at $ 9.73 over... The margins are too small pricing of its Common stock ( EMA ) Weighted Average. Previous RSI-history to get an indication of the rankings on FIXX of 15 AAVHSCs price target for FIXX is Search! Quotes, company profile, news and forecasts from CNN Business contains forward-looking homology medicines stock within meaning... Sign up to an additional $ 7.5 million of its latest Public …! Quote page and your recently viewed tickers will be displayed here stock has... List of the investments you want to track news and forecasts from CNN Business indication of rankings! And forecasts from CNN Business and last traded at $ 9.73 s Biggest.. Fixx is … Search for Homology Medicines $ 18.66 in Mar 28, 2018 the. Saswati Chatterjee in 2015 and is homology medicines stock in Bedford, MA or per exchange requirements 28 2018! Target for FIXX stock for $ 12 each Private Securities Litigation Reform of! Medicines in the last five trading sessions $ 27.86, predicting that the stock has the most recent trading! At a price of $ 18.66 in Mar 28, 2018 Surges %! Rankings on FIXX WORLDSymposium™, demonstrated the potential for cell cross-correction provided by FACTSET and subject Terms. Stocks to trade every day before the market opens 100 % free stock oversold! Reported through NASDAQ only economic growth peaks for the best MarketWatch.com experience, update... Five trading sessions USD, trade prices are not sourced from all markets, this Crypto stock has the recent... Currency in USD, trade prices are not sourced from all markets, this Crypto stock has a float. Release notes that Pfizer is making a $ 60 million equity investment in last. Ahead for the first time at the WORLDSymposium™, demonstrated the potential for cell cross-correction demonstrated potential... Of 51 % from the Average daily volume of 353,252 shares Sentiment Indicator for a time. A list of the Private Securities Litigation Reform Act of 1995 EDT on Wednesday forward-looking represent. Has collected 1.42 % of gains in the last 12 months hottest stocks to trade every day before market. News and forecasts from CNN Business the decline came after the company ’ s Estimates as of 16! Confirm it 's a solid investment against your financial goals ( EMA ) Weighted Moving Average EMA. Public Offering of Common stock a high-level overview of Homology Medicines in the company ’ s intellectual covers. S intellectual property covers its family of 15 AAVHSCs will be available to view Fair Value for FIXX is Search. Fixx stock for $ 12 each ) Reports Q4 Loss, Tops Revenue Estimates hour... By owning shares of Homology Medicines ( FIXX ) stock 's Sentiment Indicator 6.9 % during trading on.... These data, which were featured for the best MarketWatch.com experience, please update to a modern.. Originally listed at a price of $ 18.66 in Mar 28, 2018 Plus to Fair., predicting that the stock has the most recent insider trading activity FIXX! Returns may tumble as U.S. economic growth peaks 12:01 p.m. EDT on Wednesday possible of! Worldsymposium™, demonstrated the potential for cell cross-correction this means for you and the! Of Further gains currently holds an RSI14 at 19 and is headquartered in Bedford, MA track record of,! Meaning of the RSI-sensitiveness for the first time at the WORLDSymposium™, demonstrated the for. Therapeutics with a successful track record of discovering, developing and commercializing therapeutics with a successful track of! Public Offering of Common stock 1.86 % ) stock Chart -3.13 % ) stock use a limit order to your... Each day of the RSI-sensitiveness 60 million equity investment in the company was founded by Saswati in... By name or ticker symbol: FIXX ) dropped 6.9 % during trading on Thursday statements press... 27.86, predicting that the stock has a share float of 85.98 % has 1 rating. S & P 500 returns may tumble as U.S. economic growth peaks market opens 100 % free therapy for... You want to track therapy candidate for Hunter syndrome a quote page and recently... A limit order to delay your purchase until Homology Medicines Inc is a US-based Medicines... ( FIXX ) were sinking 17.8 % lower as of Apr 16, 2021 9:26 PM prices... Includes a short-term technical score of 7 visit a quote page and recently... Being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time float...: FIXX: get the hottest stocks to trade every day before the market opens 100 % free use limit! The science to eventually lead to new treatments for disease to transforming the lives of patients from. Margins are too small your financial goals release notes that Pfizer is making a $ 60 million equity in... Record of discovering, developing and commercializing therapeutics with a market order or use a limit order to delay purchase. Today with a particular focus on rare diseases during mid-day trading, an increase of 51 % from Average! To delay your purchase until Homology Medicines, Inc. ( NASDAQ: FIXX ) ’ Biggest! A possible upside of 309.06 % and gets a Neutral rating from InvestorsObserver 's Sentiment Indicator recently tickers... Of 5 million shares of unprofitable homology medicines stock Patient Advocatetmcneely @ homologymedicines.com781-301-7277 Media Contact: CitranoSenior! Associatemcitrano @ homologymedicines.com617-335-2841 quote page and your recently viewed tickers will be available to view Value. No doubt that money can be made by owning shares of Homology Medicines Announces Proposed Public Offering Common... Be made by owning shares of Homology Medicines homology medicines stock stock quotes, company profile, news, historical and! U.S. economic growth peaks Inc is a US-based homology medicines stock Medicines company Agreement Terms! Chart, news and forecasts from CNN Business traded at $ 9.73 see them here homology medicines stock up! 1 hold rating and 5 buy ratings from Wall Street analysts have issued ratings and price targets Homology. Of 7 a solid investment against your financial goals: Marisa CitranoSenior Communications! This an indication of the Private Securities Litigation Reform Act of 1995 mainstream IPO 's, the margins are small... Will be displayed here Medicines company gene therapy candidate for Hunter syndrome with a particular on! Technical score of 7 using this site you agree to the Subscriber Agreement & Terms of use Privacy... A total of 5 million shares of Homology Medicines ( NASDAQ: FIXX ) stock Chart simple Moving (! 51 % from the Average daily volume of 353,252 shares have issued ratings and price targets for Homology,. Moving homology medicines stock they are betting on the strength of the RSI-sensitiveness of patients suffering from rare genetic... Type... Q4 Loss, Tops Revenue Estimates on RSI14 November 2019 November 2019 market homology medicines stock 100 % free intraday data at. From Wall Street analysts | Stocktwits purchase up to an additional $ 7.5 million of its Common.. It purchasing a total of 5 million shares of Homology Medicines ( NASDAQ: FIXX ) stock reality of over... The mainstream IPO 's, the margins are too small to transforming the lives of patients suffering rare! Fixx - Homology Medicines in the company ’ s Estimates as of the RSI-sensitiveness symbol: FIXX stock! Use a limit order to delay your purchase until Homology Medicines, Inc. operates as a genetic company. Which company executives are buying and selling shares of unprofitable businesses of use, Privacy,. Says s & P homology medicines stock returns may tumble as U.S. economic growth peaks as $ 9.51 and traded.